Navitor Pharmaceuticals closes $23.5 mln Series A

Biopharmaceutical company Navitor Pharmaceuticals has closed a $23.5 million Series A financing. Investors include Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund. Inc.

Aduro BioTech secures $55 mln Series C

Clinical stage biotechnology company Aduro BioTech has closed a $55 million Series C financing. New investor Johnson & Johnson Development Corporation joined the Morningside group and other new and existing investors in the transaction.

CVRx Closes $29.6m Financing

CVRx, a private medical device company, has completed a financing round totaling $29.6 million. CVRx plans to use the funding for advancing its clinical trials and expanding its international commercial activities. New Enterprise Associates and Johnson & Johnson Development Corporation were the co-lead investors. Other participants in this round included existing investors BBT Fund L.P. and SightLine Partners.

Celladon Wraps Up $43M Round

Celladon Corp., a developer of treatments for cardiovascular diseases, has closed on $43 million in new capital. Pfizer Venture Investments led the round, which included investment from new backers Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, and GBS Venture Partners. All previous investors participated in this round, including Enterprise Partners Venture Capital, Johnson […]

PowerVision Completes Funding Round

PowerVision, a private company developing an accommodating intraocular lens, had added Johnson & Johnson Development Corporation to its list of investors in a recent closing of its Series C financing. Current investors, Venrock, Advanced Technology Ventures, and Frazier Healthcare Ventures, also participated in the round. The closing brings PowerVision’s Series C financing round to a […]

Catalyst Biosciences Inks $7M from Phizer

Catalyst Biosciences Inc. has sealed a $7 million milestone payment from Pfizer, as part of a research and license agreement between the two companies. Catalyst recently initiated Phase 1 clinical trials for one of its products, designed to help treat hemophilia patients. Privately held Catalyst is backed by investors including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures.

Nevro Inks $58M For Chronic Pain Treatment

Menlo Park, Calif.-based Nevro Corp., a neuromodulation company focused on relief of chronic pain, has sealed a whopping $58 million round led by new investor Johnson & Johnson Development Corporation. Existing shareholders Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Mayo Clinic, MPM Capital and Three Arch Partners also participated. The money will go toward a clinical study in the US and to support the company’s commercialization strategy.

VC-backed Genocea Names Chip Clark CEO

Cambridge, Mass.-based vaccine development company Genocea Biosciences has named Chip Clark president and chief executive officer. Clark joined the company last August as chief business officer. Genocea is backed by investors including Johnson & Johnson Development Corporation, Skyline Ventures, MP Healthcare Venture Management and Polaris Venture Partners.

PE HUB Community

Join the 12523 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget